BMRN
Price
$56.05
Change
+$0.91 (+1.65%)
Updated
Oct 15 closing price
Capitalization
11.51B
18 days until earnings call
Intraday BUY SELL Signals
IBO
Price
$3.16
Change
-$0.24 (-7.06%)
Updated
Oct 15 closing price
Capitalization
47.93M
Intraday BUY SELL Signals
Interact to see
Advertisement

BMRN vs IBO

BMRN vs IBO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BMRN vs. IBO commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and IBO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BMRN with price predictions
Oct 15, 2026

BMRN in downward trend: price dove below 50-day moving average on September 22, 2026

BMRN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMRN as a result. In 55 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The 10-day moving average for BMRN crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

The Aroon Indicator for BMRN entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Oscillator exited the oversold zone, 20 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 166 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.821) is normal, around the industry mean (26.782). P/E Ratio (160.703) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (437.542).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for IBO with price predictions
Oct 15, 2026

Momentum Indicator for IBO turns negative, indicating new downward trend

IBO saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In 36 of the 39 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IBO turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In 13 of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

IBO moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IBO broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBO entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +18.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 67 of 85 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.452) is normal, around the industry mean (26.782). P/E Ratio (0.505) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. IBO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BMRN vs IBO: Fundamental Ratings
BMRN
IBO
OUTLOOK RATING
1..100
5996
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
898
PRICE GROWTH RATING
1..100
6193
P/E GROWTH RATING
1..100
236
SEASONALITY SCORE
1..100
5030

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBO's Valuation (73) in the null industry is in the same range as BMRN (93) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.

IBO's Profit vs Risk Rating (100) in the null industry is in the same range as BMRN (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.

IBO's SMR Rating (8) in the null industry is significantly better than the same rating for BMRN (89) in the Biotechnology industry. This means that IBO’s stock grew significantly faster than BMRN’s over the last 12 months.

BMRN's Price Growth Rating (61) in the Biotechnology industry is in the same range as IBO (93) in the null industry. This means that BMRN’s stock grew similarly to IBO’s over the last 12 months.

BMRN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for IBO (36) in the null industry. This means that BMRN’s stock grew somewhat faster than IBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNIBO
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 28 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
60%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (BMRN: $56.05 vs. IBO: $3.16)
Brand notoriety: BMRN and IBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 133% vs. IBO: 179%
Market capitalization -- BMRN: $11.51B vs. IBO: $47.93M
BMRN [@Biotechnology] is valued at $11.51B. IBO’s [@Biotechnology] market capitalization is $47.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 1 FA rating(s) are green while IBO’s FA Score has 1 green FA rating(s).

  • BMRN’s FA Score: 1 green, 4 red.
  • IBO’s FA Score: 1 green, 4 red.
According to our system of comparison, IBO is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 4 TA indicator(s) are bullish while IBO’s TA Score has 3 bullish TA indicator(s).

  • BMRN’s TA Score: 4 bullish, 5 bearish.
  • IBO’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BMRN is a better buy in the short-term than IBO.

Price Growth

BMRN (@Biotechnology) experienced а +2.11% price change this week, while IBO (@Biotechnology) price change was -23.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.57%. For the same industry, the average monthly price growth was -12.13%, and the average quarterly price growth was -18.10%.

Reported Earning Dates

BMRN is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-5.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BMRN
Daily Signal:
Gain/Loss:
IBO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QTEX1.580.12
+8.22%
QTREX Quantum Ltd.
OPRA18.170.65
+3.71%
Opera Limited
NFLX72.612.04
+2.89%
Netflix Inc.
CIFR10.040.10
+1.01%
Cipher Digital Inc.
IA18.89-0.29
-1.51%
Innovative Solutions & Support Inc

IBO and

Correlation & Price change

A.I.dvisor tells us that IBO and PCSA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IBO and PCSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
-7.20%
PCSA - IBO
32%
Poorly correlated
+4.02%
INDP - IBO
27%
Poorly correlated
+28.96%
LPCN - IBO
27%
Poorly correlated
-0.59%
IVVD - IBO
25%
Poorly correlated
+10.04%
LIMN - IBO
24%
Poorly correlated
N/A
More